🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Adebellizumab

    The First People's Hospital of Lianyungang

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  3. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  4. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. Administration of experimental treatment association (sotorasib, panitumumab 5FU)

    NORTHWEST BIOTHERAPEUTICS INC

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  6. Advair HFA

    United Therapeutics Europe Ltd

    Altitude Edema

    phase 2 small molecule active

    1 trial

  7. Aerobic exercise training

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 other completed

    1 trial

  8. Aerosolized lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  9. Afatinib and Paclitaxel

    United Therapeutics Europe Ltd

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  10. Aglatimagene besadenovec

    Candel Therapeutics

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 mab active

    1 trial

  11. Aglatimagene besadenovec

    Candel Therapeutics

    Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  12. Aldesleukin

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  13. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial

  14. Aleniglipron

    Structure Therapeutics

    Obese

    phase 2 small molecule active

    1 trial

  15. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  16. Alisertib

    Takeda

    Adenocarcinoma of the Prostate

    phase 2 small molecule completed

    1 trial

  17. All-trans Retinoic Acid in combination with the KPD Regimen

    The First People's Hospital of Lianyungang

    Multiple Myeloma in Relapse

    phase 2 small molecule active

    1 trial

  18. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  19. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  20. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial

  21. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  22. Allopregnanolone injection

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule completed

    1 trial

  23. Almonertinib

    The First People's Hospital of Lianyungang

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Almonertinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources